Genus plc (LON:GNS - Get Free Report) crossed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of GBX 1,810.28 ($23.47) and traded as high as GBX 1,994 ($25.86). Genus shares last traded at GBX 1,992 ($25.83), with a volume of 87,838 shares trading hands.
Analyst Upgrades and Downgrades
Separately, Shore Capital reissued a "buy" rating on shares of Genus in a research report on Wednesday, December 11th.
Read Our Latest Research Report on GNS
Genus Price Performance
The company has a current ratio of 1.80, a quick ratio of 1.08 and a debt-to-equity ratio of 53.12. The company has a market cap of £1.28 billion, a PE ratio of 161.64, a P/E/G ratio of 2.87 and a beta of 0.37. The firm has a 50 day moving average of GBX 1,817.83 and a two-hundred day moving average of GBX 1,815.26.
Genus (LON:GNS - Get Free Report) last released its earnings results on Thursday, February 27th. The company reported GBX 39.80 ($0.52) EPS for the quarter. Genus had a return on equity of 1.41% and a net margin of 1.18%. Research analysts predict that Genus plc will post 70.9644323 earnings per share for the current fiscal year.
Insider Buying and Selling at Genus
In other news, insider Jorgen Kokke sold 19,967 shares of the stock in a transaction that occurred on Friday, February 28th. The shares were sold at an average price of GBX 1,731 ($22.45), for a total transaction of £345,628.77 ($448,170.09). 0.75% of the stock is owned by company insiders.
About Genus
(
Get Free Report)
Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It sells breeding pigs and semen to breed pigs with various characteristics for pork production under the PIC brand.
Featured Stories
Before you consider Genus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genus wasn't on the list.
While Genus currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
